Your SlideShare is downloading. ×
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share

331

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
331
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Leukemia Therapeutics Market to 2018 - Strong Late-stagePipeline to Sustain Branded Drugs Major Market ShareReport Details:Published:November 2012No. of Pages: 145Price: Single User License – US$3500Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded DrugsMajor Market ShareSummaryGBI Research, the leading business intelligence provider, has released its latest research“Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded DrugsMajor Market Share” which provides insights into leukemia therapeutics market until 2018 for fourmajor indications. The report is built using data and information sourced from proprietarydatabases, primary and secondary research and in-house analysis by GBI Research’s team ofindustry experts.The report provides an in-depth analysis of the major leukemia indications including acutelymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia(AML) and chronic myelocytic leukemia (CML). The report examines the global leukemia diseasestreatment usage patterns. In addition, the geographical distribution of leukemia therapeutics andmarkets across the US, the top five countries of Europe and in Japan are provided in the report.The report also includes insights into the leukemia therapeutics R&D product pipeline andexplores the competitive landscape including major players in the leukemia therapeutics market.Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensingagreements that took place in leukemia therapeutics market.In 2011, the leukemia therapeutics market for four major leukemia indications was estimated at$4.0 billion, indicating a compound annual growth rate (CAGR) of 21.0% since 2004. GBIResearch forecasts the market to grow at a CAGR of 9.5% between 2011 and 2018 to reach to$7.6 billion by 2018. The four indications covered are treatment of acute lymphocytic leukemia(ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML) and chronicmyelogenous leukemia (CML). The historic growth in major markets such as the US, the top fivecountries of Europe and Japan were driven mainly by the increasing prevalence and prescription
  • 2. population as well as launch of newer brands such as Sprycel, Tasigna, Clolar and Arranon withno major patent expirations. The US was the leading market with an estimated sales value of $1.8billion in 2011 and an approximate share of 44.3%. The US market is expected to grow at a CAGRof 10.0% between 2011 and 2018 to record sales value of $3.5 billion in 2018. The top fivecountries of Europe together contributed to sales worth $1.5 billion in 2011, accounting for anapproximate share of 37.9%. The top five countries of Europe are expected to record sales worth$3.1 billion by the year 2018, at a CAGR of 10.3%. Japan, in 2011, contributed $720m to theglobal market increasing at a CAGR of 20.8% from 2004. It accounts for an approximate share of17.8%. Growing at a CAGR of 6.1% between 2011 and 2018, the market is expected to recordsales worth $1.1 billion by 2018.Scope- Data and analysis on the leukemia therapeutics market in the leading geographies of the world –the US, Japan, the UK, Germany, France, Italy and Spain- Annualized market data for the leukemia therapeutics market from 2004 to 2011, with forecaststo 2018- Market data on the geographical landscape and therapeutic landscape, including market size,market share, annual cost of therapy, sales volume and treatment usage patterns such as diseasepopulation, treatment seeking population, diagnosis population and prescription population- Key drivers and restraints that have had a significant impact on the market- The competitive landscape of the global leukemia therapeutics market including top companiesbenchmarking. The key companies studied in this report are Novartis AG, GlaxoSmithKline plc(GSK), Genzyme Corporation, Bristol-Myers Squibb Company (BMS) and Eisai Co., Ltd.- Key M&A activities and licensing agreements that took place in 2009 and 2011 in the leukemiatherapeutics market.Reasons to buy- Align your product portfolio to the markets with high growth potential.- Build effective strategies to launch their pipeline products by identifying potential geographies.- Exploit in-licensing and out-licensing opportunities by identifying products that might fill theirportfolio gaps.- Develop key strategic initiatives by studying the key strategies of top competitors.- Device a more tailored country strategy through the understanding of key drivers and barriersand market potential of each indication.- Develop market-entry and market expansion strategies by identifying the geographic marketspoised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-classmolecules which are safer and more efficacious.Get your copy of this report @
  • 3. http://www.reportsnreports.com/reports/202048-leukemia-therapeutics-market-to-2018-strong-late-stage-pipeline-to-sustain-branded-drugs-major-market-share.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 102 Leukemia Market to 2018 - Introduction 123 Leukemia Market to 2018 - Market Overview 133.1 Introduction 133.1.1 Revenue 133.1.2 Annual Cost of Treatment 153.1.3 Treatment Usage Pattern 163.2 Drivers and Barriers 183.2.1 Drivers for the Leukemia Therapeutics Market 183.2.2 Barriers for the Leukemia Therapeutics Market 194 Leukemia Market to 2018 - Geographical Landscape 204.1 Revenue Analysis by Geography 204.2 The US 224.2.1 Revenue 224.2.2 Annual Cost of Therapy 234.2.3 Treatment Usage Pattern 244.3 Top Five Countries of Europe 264.3.1 Revenue 264.3.2 Annual Cost of Therapy 284.3.3 Treatment Usage Pattern 304.4 Japan 324.4.1 Revenue 324.4.2 Annual Cost of Therapy 334.4.3 Treatment Usage Pattern 345 Leukemia Market to 2018 - Therapeutic Landscape 365.1 Acute Lymphocytic Leukemia (ALL) Therapeutics Market 365.1.1 Introduction 365.1.2 Classification 375.1.3 Epidemiology 385.1.4 Signs and Symptoms 395.1.5 Treatment and Management Pattern 405.1.6 Revenue 415.1.7 Annual Cost of Treatment 465.1.8 Treatment Usage Pattern 475.1.9 Major Marketed Products 495.1.10 Drivers and Barriers for the ALL Therapeutics Market 51
  • 4. 5.2 Chronic Lymphocytic Leukemia Therapeutics Market 525.2.1 Introduction 525.2.2 Epidemiology 535.2.3 Symptoms 535.2.4 Diagnosis 535.2.5 Treatment 555.2.6 Revenue 565.2.7 Annual Cost of Treatment 605.2.8 Treatment Usage Pattern 615.2.9 Major Marketed Products 635.2.10 Drivers and Barriers for the CLL Therapeutics Market 655.3 Acute Myelogenous Leukemia Therapeutics Market 665.3.1 Introduction 665.3.2 Epidemiology 685.3.3 Symptoms 685.3.4 Staging of AML 695.3.5 Diagnosis 695.3.6 Treatment by Stage 715.3.7 Revenue 725.3.8 Annual Cost of Treatment 765.3.9 Treatment Usage Pattern 775.3.10 Major Marketed Products 795.3.11 Drivers and Barriers for the AML Therapeutics Market 805.4 Chronic Myelogenous Leukemia Therapeutics Market 825.4.1 Introduction 825.4.2 Epidemiology 825.4.3 Staging 835.4.4 Symptoms 835.4.5 Diagnosis 845.4.6 Treatment of CML 845.4.7 Revenue 855.4.8 Annual Cost of Treatment 905.4.9 Treatment Usage Pattern 915.4.10 Major Marketed Products 935.4.11 Drivers and Barriers for the CML Therapeutics Market 966 Leukemia Market to 2018 - Pipeline Analysis 986.1 Introduction 986.2 Pipeline Assessment by Indication 1006.2.1 Acute Lymphocytic Leukemia 1006.2.2 Chronic Lymphocytic Leukemia 1016.2.3 Acute Myelogenous Leukemia 1026.2.4 Chronic Myelogenous Leukemia 103
  • 5. 6.3 Profiles of Promising Molecules for Leukemia 1046.3.1 DepoCyte (liposomal cytarabine) 1046.3.2 GRASPA (L-asparaginase) 1046.3.3 Marqibo (vincristine sulfate liposomes injection) 1056.3.4 GA101 (Obinutuzumab, RO5072759, RG7159) 1066.3.5 Revlimid (lenalidomide) 1076.3.6 Clolar (clofarabine) 1086.3.7 Dacogen (decitabine) 1096.3.8 Midostaurin (PKC 412) 1106.3.9 Quizartinib (AC220) 1116.3.10 Sapacitabine 1116.3.11 Tosedostat (CHR-2797) 1136.3.12 Vidaza (azacitadine) 1146.3.13 Vosaroxin 1156.3.14 Omapro (omacetaxine mepesuccinate) 1166.3.15 Bosutinib (SKI-606) 1177 Leukemia Market to 2018 - Competitive Landscape 1187.1 Novartis AG 1187.1.1 Company Overview 1187.1.2 SWOT Analysis 1187.2 GlaxoSmithKline plc (GSK) 1197.2.1 Company Overview 1197.2.2 SWOT Analysis 1197.3 Genzyme Corporation 1207.3.1 Company Overview 1207.3.2 SWOT Analysis 1207.4 Bristol-Myers Squibb Company (BMS) 1217.4.1 Company Overview 1217.4.2 SWOT Analysis 1217.5 Eisai Co., Ltd. 1227.5.1 Company Overview 1227.5.2 SWOT Analysis 1228 Leukemia Market to 2018 - Strategic Consolidations 1238.1 Analysis by Deal Type 1238.2 Analysis by Indication 1248.3 Mergers & Acquisitions 1258.3.1 Segmentation by Year 1258.3.2 Segmentation by Geography 1268.3.3 Segmentation by Value 1278.3.4 Major Mergers and Acquisitions 1278.4 Licensing Agreements 1298.4.1 Segmentation by Year 129
  • 6. 8.4.2 Segmentation by Geography 1308.4.3 Segmentation by Value 1318.4.4 Major Licensing Agreements 1328.5 Co-development Deals 1348.5.1 Segmentation by Year 1348.5.2 Segmentation by Geography 1358.5.3 Segmentation by Value 1358.5.4 Major Co-Development Deals 1369 Leukemia Market to 2018 - Appendix 1379.1 Market Definitions 1379.2 Abbreviations 1379.3 Bibliography 1399.4 Research Methodology 1409.4.1 Coverage 1409.4.2 Secondary Research 1419.4.3 Primary Research 1419.4.4 Therapeutic Landscape 1429.4.5 Market Size by Geography 1449.4.6 Geographical Landscape 1459.4.7 Pipeline Analysis 1459.4.8 Competitive Landscape 1459.4.9 Expert Panel Validation 1459.5 Contact Us 1459.6 Disclaimer 1451.1 List of TablesTable 1: Leukemia Market to 2018, Global, Revenue ($bn), 2004-2011 13Table 2: Leukemia Market to 2018, Global, Revenue Forecasts ($bn), 2011-2018 13Table 3: Leukemia Market to 2018, Global, Annual Cost of Treatment ($), 2004-2011 15Table 4: Leukemia Market to 2018, Global, Annual Cost of Treatment Forecasts ($), 2011-2018 15Table 5: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand),2004-2011 16Table 6: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand)Forecasts, 2011-2018 17Table 7: Leukemia Market to 2018, Global, Revenue, By Country ($m), 2004-2011 20Table 8: Leukemia Market to 2018, Global, Revenue Forecasts, By Country ($m), 2011-2018 21Table 9: Leukemia Market to 2018, The US, Revenue ($m), 2004-2011 22Table 10: Leukemia Market to 2018, The US, Revenue Forecasts ($m), 2011-2018 22Table 11: Leukemia Market to 2018, The US, Annual Cost of Treatment ($), 2004-2011 23Table 12: Leukemia Market to 2018, The US, Annual Cost of Treatment Forecasts ($), 2011-201823Table 13: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand),
  • 7. 2004-2011 24Table 14: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand)Forecasts, 2011-2018 25Table 15: Leukemia Market to 2018, Top Five Countries of Europe, Revenue ($m), 2004-2011 26Table 16: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts ($m),2011-2018 26Table 17: Leukemia Market to 2018, Top Five Countries of Europe, Revenue, By Country ($m),2004-2011 27Table 18: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts, ByCountry ($m), 2011-2018 28Table 19: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment ($),2004-2011 29Table 20: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment ($)Forecasts, 2011-2018 29Table 21: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern,Population (thousand), 2004-2011 30Table 22: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern,Population (thousand), 2011-2018 31Table 23: Leukemia Market to 2018, Japan, Revenue ($m), 2004-2011 32Table 24: Leukemia Market to 2018, Japan, Revenue Forecasts ($m), 2011-2018 32Table 25: Leukemia Market to 2018, Japan, Annual Cost of Treatment ($), 2004-2011 33Table 26: Leukemia Market to 2018, Japan, Annual Cost of Treatment ($), 2011-2018 33Table 27: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population, 2004-2011 34Table 28: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population Forecasts,2011-2018 35Table 29: Leukemia Market to 2018, Acute Lymphocytic Leukemia, FAB Classification, 2012 37Table 30: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Incidence Rate by Age, 200738Table 31: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Incidence Rates by Race,2007 39Table 32: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Treatment: TargetedChemotherapy 41Table 33: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue ($m), 2004-2011 42Table 34: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecasts($m), 2011-2018 42Table 35: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue By Country($m), 2004-2011 43Table 36: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecast ByCountry ($m), 2011-2018 44Table 37: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost ofTreatment ($), 2004-2011 46
  • 8. Table 38: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost ofTreatment Forecasts ($), 2011-2018 46Table 39: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment UsagePattern, 2004-2011 47Table 40: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment UsagePattern, 2011-2018 48Table 41: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Rai Staging System, TheUS, 2012 54Table 42: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Binet Staging System,Europe, 2012 55Table 43: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue ($m),2004-2011 56Table 44: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts($m), 2011-2018 56Table 45: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue by Country($m), 2004-2011 57Table 46: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecastsby Country ($m), 2011-2018 58Table 47: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost ofTreatment ($), 2004-2011 60Table 48: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost ofTreatment ($), 2011-2018 61Table 49: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment UsagePattern, Population (thousand), 2004-2011 62Table 50: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment UsagePattern, Population (thousand), 2011-2018 62Table 51: Leukemia Market to 2018, WHO Classification of AML, 2012 67Table 52: Leukemia Market to 2018, The French-American-British (FAB) Classification of AML,2012 68Table 53: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue ($m), 2004-2011 72Table 54: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue Forecasts($m), 2011-2018 72Table 55: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country($m), 2004-2011 74Table 56: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country($m), 2011-2018 74Table 57: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost ofTreatment ($), 2004-2011 76Table 58: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost ofTreatment ($), 2011-2018 76Table 59: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment Usage
  • 9. Pattern, Population (thousand), 2004-2011 77Table 60: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment UsagePattern, Population (thousand), 2011-2018 78Table 61: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, DiagnosisPercentage by Age Group, 2004-2008 82Table 62: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue ($bn),2004-2011 86Table 63: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue Forecasts,($bn), 2011-2018 86Table 64: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue byCountry ($m), 2004-2011 88Table 65: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue byCountry ($m), 2011-2018 88Table 66: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost ofTreatment ($), 2004-2011 90Table 67: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost ofTreatment ($), 2011-2018 90Table 68: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment UsagePattern, Population (thousand), 2004-2011 91Table 69: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment UsagePattern, Population (thousand), 2011-2018 92Table 70: Leukemia Market to 2018, Global, Mergers and Acquisitions, 2009-2011 127Table 71: Leukemia Market to 2018, Global, Licensing Agreements, 2009-2011 132Table 72: Leukemia Market to 2018, Global, Co-Development Deals, 2009-2011 1361.2 List of FiguresFigure 1: Leukemia Market to 2018, Global, Revenue Forecasts ($bn), 2004-2018 13Figure 2: Leukemia Market to 2018, Global, Branded vs. Generics (%), 2011-2018 14Figure 3: Leukemia Market to 2018, Global, Annual Cost of Treatment ($), 2004-2018 15Figure 4: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand),2004-2018 16Figure 5: Leukemia Market to 2018, Global, Drivers and Barriers 18Figure 6: Leukemia Market to 2018, Global, Revenue Forecasts, By Country ($m), 2004-2018 20Figure 7: Leukemia Market to 2018, The US, Revenue Forecasts ($m), 2004-2018 22Figure 8: Leukemia Market to 2018, The US, Annual Cost of Treatment ($), 2004-2018 23Figure 9: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand),2004-2018 24Figure 10: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts ($m),2004-2018 26Figure 11: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts, ByCountry ($m), 2004-2018 27Figure 12: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment ($),
  • 10. 2004-2018 28Figure 13: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern,Population (thousand), 2004-2018 30Figure 14: Leukemia Market to 2018, Japan, Revenue Forecasts ($m), 2004-2018 32Figure 15: Leukemia Market to 2018, Japan, Annual Cost of Treatment ($), 2004-2018 33Figure 16: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population, 2004-2018 34Figure 17: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecasts($m), 2004-2018 41Figure 18: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue By Country($m), 2004-2018 43Figure 19: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Branded vs. Generics(%), 2011-2018 45Figure 20: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost ofTreatment ($), 2004-2018 46Figure 21: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment UsagePattern, 2004-2018 47Figure 22: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Drivers and Barriers51Figure 23: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts($m), 2004-2018 56Figure 24: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue byCountry ($m), 2004-2018 57Figure 25: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Branded vs.Generics (%), 2011-2018 59Figure 26: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost ofTreatment ($), 2004-2018 60Figure 27: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment UsagePattern, Population (thousand), 2004-2018 61Figure 28: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Drivers and Barriers65Figure 29: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue Forecasts($m), 2004-2018 72Figure 30: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country($m), 2004-2018 73Figure 31: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Branded vs.Generics (%), 2011-2018 75Figure 32: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost ofTreatment ($), 2004-2018 76Figure 33: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment UsagePattern, Population (thousand), 2004-2018 77Figure 34: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Drivers and Barriers80
  • 11. Figure 35: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Different Stages ofCML 83Figure 36: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue ($bn),2004-2018 85Figure 37: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue byCountry ($m), 2004-2018 87Figure 38: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Branded vs.Generics (%), 2004-2018 89Figure 39: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost ofTreatment ($), 2004-2018 90Figure 40: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment UsagePattern, Population (thousand), 2004-2018 91Figure 41: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Drivers andBarriers 96Figure 42: Leukemia Market to 2018, Global, R&D Pipeline by Indications, 2011 98Figure 43: Leukemia Market to 2018, Global, R&D Pipeline by Phase, 2011 99Figure 44: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, R&D Pipeline, 2011100Figure 45: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, R&D Pipeline, 2011101Figure 46: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, R&D Pipeline, 2011102Figure 47: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, R&D Pipeline,2011 103Figure 48: Leukemia Market to 2018, Novartis AG, SWOT, 2011 118Figure 49: Leukemia Market to 2018, GlaxoSmithKline Plc, SWOT, 2011 119Figure 50: Leukemia Market to 2018, Genzyme Corporation, SWOT, 2011 120Figure 51: Leukemia Market to 2018, Bristol-Myers Squibb Company, SWOT, 2011 121Figure 52: Leukemia Market to 2018, Eisai Co., Ltd., SWOT, 2011 122Figure 53: Leukemia Market to 2018, Global, All Deals, by Type, 2009-2011 123Figure 54: Leukemia Market to 2018, Global, All Deals, By Indication, 2009-2011 124Figure 55: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Year, 2009-2011 125Figure 56: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Geography, 2009-2011126Figure 57: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Value, 2009-2011 127Figure 58: Leukemia Market to 2018, Global, Licensing Agreements, By Year, 2009-2011 129Figure 59: Leukemia Market to 2018, Global, Licensing Agreements, By Geography, 2009-2011130Figure 60: Leukemia Market to 2018, Global, Licensing Agreements, By Value, 2009-2011 131Figure 61: Leukemia Market to 2018, Global, Co-development Deals, By Year, 2009-2011 134Figure 62: Leukemia Market to 2018, Global, Co-Development Deals, By Geography, 2009-2011135
  • 12. Figure 63: Leukemia Market to 2018, Global, Co-Development Deals, By Value, 2009-2011 135Figure 64: GBI Research Market Forecasting Model 144Contact: sales@reportsandreports.com for more information.

×